Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $5.0 million.

  • Anika Therapeutics' Free Cash Flow rose 31.13% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $648,000, marking a year-over-year increase of 180.20%. This contributed to the annual value of -$2.3 million for FY2024, which is 67.69% up from last year.
  • Latest data reveals that Anika Therapeutics reported Free Cash Flow of $5.0 million as of Q3 2025, which was up 400.91% from -$1.7 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Free Cash Flow high stood at $5.7 million for Q3 2023, and its period low was -$9.8 million during Q2 2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$1.7 million (2025), whereas its average is -$833,909.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 1,031.99% in 2021, then skyrocketed by 464.24% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Free Cash Flow stood at $3.3 million in 2021, then plummeted by 161.23% to -$2.0 million in 2022, then skyrocketed by 187.79% to $1.8 million in 2023, then slumped by 84.71% to $275,000 in 2024, then spiked by 31.13% to $5.0 million in 2025.
  • Its Free Cash Flow stands at $5.0 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$3.0 million for Q1 2025.